Role of Vitamin D in maintaining the integrity of epidermal barrier in

INTERVENTION: Trade Name: DAIVONEX Product Name: DAIVONEX Pharmaceutical Form: Cream Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Topical use (Noncurrent) CONDITION: Psoriatic skin Therapeutic area: Diseases [C] ‐ Skin and Connective Tissue Diseases [C17] PRIMARY OUTCOME: Main Objective: Role of Vitamin D in maintaining the integrity of epidermal barrier in; psoriatic skin Primary end point(s): Evaluate the possible role of vitamin D in maintaining the integrity of; epidermal barrier in psoriatic skin Secondary Objective: Not applicable Timepoint(s) of evaluation of this end point: 60 days SECONDARY OUTCOME: Secondary end point(s): Evaluate the ability of vitamin D analogs to modify the expression of; receptors ( VDR,TLRs ), the production of antimicrobial peptides, the expression and localizzation of junctional proteins. Timepoint(s) of evaluation of this end point: 60 days INCLUSION CRITERIA: ‐Males and females aged between 18 and 65 years ‐Psoriasis with mild to moderate involvement of the body surface less than 50% ‐Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range